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Psychosocial Risks of Storing and Using
Human Tissues in Research*
Jon F. Merz**

Introduction
Human tissues are collected and stored for numerous reasons.
Many states have created forensic DNA banks;1 the U.S. military is

banking blood from soldiers with the intent to retain the samples for 50
years, 2 states are storing Guthrie cards from newborns, 3 and other
banks of newborn cord blood, tumor and normal tissues are being
created. 4 In addition, clinicians collect blood and other tissues and
samples for diagnostic tests, and pathologists are required by law and
good medical practices to retain tissues for many years (some archives
are more than a century old).
Support for this study was provided by a grant from the Annenberg Public Policy
Center to the Center for Bioethics at the University of Pennsylvania. Thanks are
extended to Peter Watson and the NCI Canada and Health Canada for support and
Michelle Parisien for assistance with the pilot study, to Peter Ubel and Peter Watson
for substantive comments on the questionnaire, to the persons who responded to the
surveys, to Peter Ubel, Pamela Sankar, Robert Levine, and several anonymous
reviewers for helpful comments on an earlier draft of the paper, and to Timothy
Rebbeck for help with the statistical analysis.
** Dr. Metz is a Research Assistant Professor of Bioethics in the Department of
Cellular and Molecular Engineering and Faculty Associate, Center for Bioethics, at
the University of Pennsylvania. He received his BS in nuclear engineering from RPI,
an MBA from the University of North Florida, a JD from Duquesne University
School of Law, and a PhD in Engineering and Public Policy from Carnegie Mellon
University. Email: merz@mail.med.upenn.edu.
1 Jean E. McEwen, Forensic DNA Data Banking by State Crime Laboratories, 56
Am. J. Hum. Genet. 1487 (1995).
2
Mayfield v. Dalton, 901 F. Supp. 300 (D. Hawaii 1995).
3 Jean E. McEwen & Phillip R. Reilly, Stored Guthrie Cards as DNA "Banks" 55
Am. J. Hum. Genet. 196 (1994).
4
See e.g., Eliot Marshall, Clinical Promise, Ethical Quandary, 271 Science 586
(1996); Jeremy Sugarman, Emily G. Reisner, Joanne Kurtzberg, Ethical Aspects of
Banking Placental Blood for Bone Marrow Transplantation, 274 J.A.MA 1783
(1995); Bartha M. Knoppers, Claude M. Laberge, Research and Stored Tissues:
Persons as Sources, Samples as Persons?274 J.A.M.A. 1806 (1995).
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Researchers also collect samples from subjects for a broad range of
studies. In many of these cases, the disposition of excess tissues has not
been a concern. However, with the rapid development of genetic
technologies has come the ability to study stored samples and generate
information about diseases and susceptibility to disease. Such
information can have profound effects on the lives of people if
irresponsibly handled or disclosed.
Because of the risks of misuse of such information, there have been
numerous calls for constraints on the banking and use of stored
tissues, 5 as well as proposals demanding detailed informed consent
6
for research uses of both stored and prospectively collected tissues.
As two leading commentators noted before genetic technologies

brought renewed focus on these issues, full disclosure or "extended
informed consent" should be secured when information developed in
proposed research with tissues might be linked to the source's identity
and when the research might yield information having diagnostic
significance that could cause stigmatization or discrimination. 7 Yet,
5 See e.g., George J. Annas, Privacy Rules for DNA Databanks: Protecting
Coded 'FutureDiaries" 270 JAM.A. 2346 (1993); George J. Annas, Leonard H.
Glantz, Patricia A. Roche, The Genetic Privacy Act and Commentary (1995) (visited
July 1997) <http://www-busph.bu.edu/Depts/LW/DOCUM.HTM>; Ellen Wright
Clayton, Karen K. Steinberg, Muin J. Khoury, Elizabeth Thomson, Lori Andrews,
Mary Jo Ellis Kahn, Loretta M. Kopelman, Joan 0. Weiss, Informed Consent for
Genetic Research on Stored Tissue Samples, 274 J.A.MA 1786 (1995).
6 See e.g., Clayton et al., supra note 5; American College of Medical Genetics
Storage of Genetics Materials Committee, Statement on Storage and Use of Genetic
Materials, 59 Am. J. Hum. Genet. 471 (1996); Robert F. Weir & Jay R. Horton,
DNA Banking and Informed Consent-Part1, 17(4) IRB: Rev. Human Subjects Res.
1 (1995); Robert F. Weir & Jay R. Horton, DNA Banking and Informed
Consent-Part2, 17(5) IRB: Rev. Human Subjects Res. 1 (1995); David E. Goldgar
& Philip R. Reilly, A Common BRCA1 Mutation in the Ashkenazim, 11 Nature
Gen. 113 (1995).
7 See e.g., Angela R. Holder & Robert J. Levine, Informed Consent for Research
on Specimens Obtainedat Autopsy or Surger: A Case Study in the Overprotection
of Human Subjects, 24 Clin. Res. 68 (1976). Genetic information is used for risk
stratification by insurers, and there are legitimate concerns that molecular genetics will
only exacerbate problems of access by those who need health insurance. Ehsan
Masood, Sally Lehrman, Quirin Schiermeier, Declan Butler, Richard Nathan, Gene
Tests: Who Benefitsfrom Risk? 379 Nature 389 (1996); Kathy L. Hudson, Karen H.
Rothenberg, Lori B. Andrews, Mary Jo Ellis Kahn, Francis S. Collins, Genetic
Discrimination and Health Insurance:An Urgent Need for Reform, 270 Science 391
(1995); Robert J. Pokorski, Genetic Information and Life Insurance, 376 Nature 13
(1995). Employers likewise can use genetic information to make employment
decisions, such as hiring, firing, or promotion. Council on Ethical and Legal Affairs,
American Medical Association, Use of Genetic Testing by Employers, 266 J.A.M.A.
1827 (1991). Discrimination risks are being addressed by a growing number of states,
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as researchers are quick to point out, securing consent from persons
whose tissues were taken for clinical or research purposes in the past is
difficult because of concerns about privacy, problems in locating and
contacting individuals, and questions about the need for consent and
the protection of human subjects when the source of the tissues has died
but relatives are available who might have valid interests in the use of
tissues that can yield information about them.
Because of these difficulties, investigators who wish to use stored
tissues in their research may avoid the burden of securing prior consent
either by having their research exempted from the oversight and
consent requirements of the federal rules8 regulating human subjects
experimentation for all federal agencies (except for the Food and Drug
Administration) or by having the need for informed consent waived by
their Institutional Review Boards (IRBs). Under these rules, research
9
may be exempt from human subjects review if it entails the
study of existing data... [and] pathological specimens or
diagnostic specimens... if the information is recorded by
the investigator in such a manner that subjects cannot be
identified, directly or through identifiers linked to the

subjects.
This requires that samples used in research have all identifying
information removed and disassociated from the tissues by removing
any linking codes that could permit investigators or anyone else
associated with the research to identify individual subjects.
Alternatively, researchers may ask IRBs to waive the informed
consent requirements. Informed consent may be modified or waived if
the IRB finds that the research presents only minimal risk to subjects,
that the waiver of consent will not adversely affect the rights or welfare
of subjects, that the research could not practicably be carried out
without the waiver, and that subjects will be provided information
about their participation afterwards, when appropriate. 1 0 Further, if a
but social stigmatization is beyond the reach of such laws.
8 45 C.F.R. 5 46.101-409 (1996).
9

45 C.F.R. § 46.101(b)(4).

10 45 C.F.R. § 46.116(d) (1996). "Minimal risk means that the probability and

magnitude of harm or discomfort anticipated in the research are not greater in and of
themselves than those ordinarily encountered in daily life or during the performance
of routine physical or psychological examinations or tests." 45 C.F.Rt § 46.102(i).
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protocol involving the study of existing data, pathological specimens, or
diagnostic specimens raises no more than minimal risk, then the
decision about waiver may be made on an expedited basis by the IRB
chair or by one or more experienced reviewers designated by the
chair. 11 If so approved, then research may proceed with linked or even
directly identified tissues.
Waiver of informed consent and expedited review are predicated
upon the determination that the research poses no more than minimal
risk. It is clear that, in the past, just about any research involving the
study of existing pathological or diagnostic specimens was broadly
considered to "present no more than minimal risk to subjects." 12 Yet,
explicit in the recent analyses of Annas, 1 3 Clayton et al.,1 4 and others
is that the risks posed by germ-line genetics research with stored tissues
are greater than minimal, if subjects are identifiable. 1 5 Identifiable
means that individual identity is manifest with the tissue or data or that
individuals can be identified by use of a linking code. If the risks of
research with stored tissues are not minimal, then either complete deidentification and de-linking of tissues to render them irreversibly
anonymous or express consent from subjects is necessary before using
those tissues in germ-line genetics studies.
We decided to explore whether those with experience in biomedical
research and bioethics perceive the riskiness of genetics research as being
more than minimal. We also wanted to examine whether the problems
posed by genetics research and storage of tissues are salient to persons in
these communities.

11 45 C.F.R. §46.110 (1995).
12 46 F.R. 8366-8391, 8380 (January 26, 1981).
13 Supra note 5.
14 Supra note 5.
15 See e.g., Jon F. Merz, Is Genetics Research 'Minimal Risk'? 18(6) IRB: Rev.
Human Subjects Res. 7 (1996) (discussing substantive differences between clinical and
research genetics activities and the evolving standard of prior counseling and informed
consent in clinical use of these technologies); Philip R. Reilly, Mark F. Boshar, Steven
H. Holtzman, Ethical Issues in Genetic Research: Disclosure and Informed Consent,
15 Nature Genet. 16, 19 (1997) (noting that past judgments of minimal risk are
probably inadequate for genetics research studies).
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The Questionnaire
We developed a simple questionnaire, presenting extremely general
descriptions of two research protocols involving a blood draw:
A. How risky to healthy adult subjects do you believe
biomedical research is which involves the collection of a
single vial of blood for research on the causes of disease?
B. How risky to healthy adult subjects do you believe
biomedical research is which involves the collection of a
single vial of blood for storage and use in future research on
the role of germ-line genetic mutations in causing disease?
We first asked respondents to rate the "riskiness" of the protocol. The
activities of Protocol B are implicitly subsumed in those circumscribed
by Protocol A. That is, when blood is taken for the purpose specified in
Protocol A, excess tissue will often be stored and may be available for
future studies as described by Protocol B. Arguably the risks of
Protocol A should be comparable or marginally larger because the
description covers a broader category of research. Nonetheless, because
we did not believe that respondents would think of the secondary uses
of blood taken for one purpose, we hypothesized that respondents
would be more likely to identify the risks associated with generation of
genetic information and loss of confidentiality in Protocol B and rate it
as more risky than Protocol A.
We also asked respondents to identify any risks or consequences
that came to mind when judging the riskiness of each protocol. We
hypothesized that respondents who identified any risks arising from the
generation of genetic information (which we term "genetics risks",
including, e.g., stigmatization, insurer or employer discrimination,
breach of confidentiality, and discovery of unwanted and uncertain
information about future disease risks) would rate the riskiness of each
protocol higher than respondents who did not identify those risks.
Finally, we asked respondents their age, gender, education, and
whether they have ever served on an IRB. IRB approval was secured for
a pilot study and for a survey of subscribers to the "mcwbioethics" and
"mcw-irb" discussion lists maintained at the Medical College of
Wisconsin (MCW). These two studies varied in design, and are
described separately below. The main hypotheses were to be examined
by analysis of variance and linear regression.
8 Risk: Health, Safety & Environment 235 [Summer 19971

Pilot Study

Method
The questionnaire was piloted with attendees of the NCIC/Terry
Fox and Health Canada Workshop on Tumor Tissue Banks held in
Toronto in mid-April, 1996. A "between-subject" design was used, and
a questionnaire presenting either Protocol A or B was placed in
attendees' information packets. Surveys were collected throughout and
after the workshop. No compensation was offered to respondents.
Responses to the risk rating question was elicited with the scale
shown in Figure 1.
Figure 1
Scale Used for Risk Elicitation in the Pilot Study
+

--------------------------------------------------

no
risk

minimal
risk

low
risk

medium
risk

high
risk

very high
risk

Results
There were 65 attendees from various institutions throughout
Canada, with several individuals from the US. Twenty nine responses
(45%) to the questionnaire were collected. Repondents on average were
44 years of age (standard deviation (SD) = 6.8, range 33-60), seventeen
were male (59%), 24 (83%) had an MD degree, and 10 (34%) had
IRB experience. Sixteen respondents received Protocol A, and 13
received Protocol B. Twenty respondents (69%) identified genetics
risks in the protocols, and there was no difference in the fraction doing
so based on which question they received.
There was no main effect of protocol form on risk judgments. This
most likely occurred because many respondents filled out the
questionnaire shortly after two plenary speeches on the ethical issues of
tissue banking, including one by the author, which were given at the
beginning of the meeting. There was, however, a strong main effect on
risk judgments with identification of any genetics risks. Respondents
who identified those risks on average rated the risk 1.2 ratings higher
than others (Mann-Whitney test Z = -2.34, p = 0.02).
Exploratory regression analysis suggested no relationship between
risk ratings and age, whether the respondent held an MD or not, or IRB
experience. There was weak evidence that female respondents had a
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tendency to rate the risks higher than males, with an average risk
evaluation for females identifying the genetics risks of 1.3 ratings higher
than males likewise identifying those risks (Mann-Whitney test Z = -

1.42, p = 0.15).
This pilot suggested that the questions were understandable to
respondents. To increase our power to study our first hypothesis, we
decided to perform a "within-subject" study.
Discussion Group Survey

Method
Permission was granted by the moderators of the MCW Bioethics
Discussion Forum and the MCW Institutional Review Board Forum to
solicit list subscribers for participation in the survey. We posted an
introductory paragraph inviting subscribers to complete the survey.
Protocol A was then presented along with the question asking
respondents to identify the risks that came to mind when responding
and questions eliciting demographic information (age, gender, highest
degrees and past or present IRB experience). The instructions asked
respondents to respond to the author, not the list, and specified that
this was the first part of a two-part survey. No compensation was
offered for participation.
The scale in Figure 2 was used to elicitate risk ratings. When
subscribers responded, Protocol B was emailed directly to them with
the risk scale and the risk identification question. Presentation order
was unvaried because the intent was to see how salient were risks from
genetics research in the generally described protocol.
Figure 2

Scale Used for Risk Elicitation in the Bioethics and IRB Forum Surveys.

1 no risk
2 minimal risk
3 a minor increase over minimal risk
4 low risk
5 medium risk
6 high risk
7 very high risk
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Results
The survey was posted to an estimated 811 subscriber list. A total of
96 responses was received to the first survey question (12%). These
respondents were treated as a convenience sample because of their
availability and likely interest, not because they are representative of the
greater sample either of subscribers to these lists, IRB members or staff,
or bioethicists generally. Of the 96 respondents, eight stated that one or
both protocols were too ambiguous to provide risk judgments or
provided alternative assessments based on subject identifiability or
linkage of identities and whether the research was genetic in nature.
Also, sixteen who responded to the first question did not respond to
the second. Responses of these two groups were omitted from further
analysis. Two days after the survey was posted, a response was posted
back to the entire list, and Protocol B was mistakenly posted by the
author to the entire list instead of back only to the respondent. Because
of the risk of contamination of the results, enrollment was curtailed
thereafter, and the responses of an additional four individuals were
omitted from further analysis. In sum, a total of 68 responses were
received containing at least one risk judgment; 60 respondents provided
numerical risk judgments for both protocols. Risk ratings that were
given as ranges of values were coded at the midpoint value.
Respondents were on average 44 years of age (SD = 9.3, range
24-73). Forty one respondents were male (60%), fourteen (21%) hold
an MD, ten (15%) hold a law degree, 32 (47%) hold a PhD, and 55
(81%) currently serve or have served on an IRB. Female respondents
were slightly less likely than males to hold an MD (2 (7%) of 27;
continuity corrected %2 = 3.52 with ldf, p = 0.06) or a PhD (7 (22%)
of 27; X2 = 8.03 with 1 df, p = 0.005).
Our first hypothesis was that respondents would rate Protocol B as
more risky than Protocol A. The mean risk rating of Protocol A was 2.9
(SD = 1.5, range 1-7)), and the mean risk rating of Protocol B was 4.4
(SD = 1.8, range 2-7). This difference is significant (Mann-Whitney
test Z = -4.80, p<0.0001) and supports our hypothesis. A histogram of
responses is provided in Figure 3. Risk categories are listed along the Xaxis. This figure shows the total number of respondents who chose each
risk value for Protocol A, on the left, and Protocol B, on the right. The
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darker portion of each column shows the number of respondents
picking that risk value who identified no or only physical risks and the
lighter shows the number that identified any genetics risks. The
distribution of risk ratings of Protocol A has a mode of 2, while the
distribution of ratings of Protocol B has modes of 2 and 5.
Figure 3
Protocol A

Protocol B
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t30
0

0

~20
E10

0

1

2
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Risk Rating

7

12

Elmrf

3 4 5
6
Risk Rating

7

The second hypothesis was that respondents would rate the riskiness
of each protocol as higher if they identified any genetics risks in the
protocols. Protocol B was designed to elicit those risks. Our test of this
hypothesis has two parts. First, we examine whether there is a difference
in the risk ratings on protocols A and B between respondents who
identified any genetics risks for each protocol and those who did not.
Of 63 responses on Protocol A, 38 (60%) identified no or only the
physical risks of a blood draw (including pain, hematoma, infection,
bleeding, fainting, and nerve or tissue damage), and their mean risk
rating was 2.2 (SD = 0.7). Twenty-five respondents (40%) identified
some genetics risks, and their average riskiness rating of the protocol
was 3.9 (SD = 1.9). Again, this is a significant difference between these
groups (Mann-Whitney test Z = -4.19, p<0.0001).
Of 65 responses on Protocol B, 14 (22%) identified no or only the
physical risks with a mean risk rating of 2.3 (SD = 0.8), and 51 (78%)
identified genetics risks with a mean risk rating of 5.0 (SD = 1.5). This
is again a significant difference (Mann-Whitney test Z = -4.82,
8 Risk. Health, Safety & Environment 235 [Summer 1997]

p<0.0001). Also, as we hypothesized, while 30 of 68 respondents (44%)
identified genetics risks in Protocol A, 53 of 68 (78%) did so on
Protocol B (X2 = 16.4 with 1 df, p<0.0001). No respondents who
identified a genetics risk on Protocol A failed to do so on Protocol B.
These differences in risk ratings are apparent in Figure 3. For both
protocols, the risk ratings for those identifying any genetic risks are
distributed more broadly and higher on the response scale.
Second, to explore whether any demographic factors were related
to respondents' risk judgments, linear regression was used. This analysis
showed that risk ratings on Protocol A were related significantly only to
whether or not respondents identified any genetics risks. Further, we
examined respondents' differential risk judgments for the 60
respondents who provided numerical risk values for both protocols.
Figure 4
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The differential was calculated by subtracting respondents' risk
judgments on Protocol A from their judgments on Protocol B.
Individuals' responses to the two protocols are shown in Figure 4. A
linear regression model showed that: (1) respondents' risk judgments
16 The number of respondents whose Protocol B risk ratings (2-7) followed initial
Protocol A risk ratings (1-7). Differential risk ratings are the rating given for Protocol
B less that given for Protocol A for each respondent.
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shifted more between Protocol A and Protocol B if they initially
identified any genetics risks on Protocol A (3 = 2.2, t = 5.05,
p<0.0001), mediated by an initial higher risk ratings of Protocol A (P =
-0.57, t = 5.10, p<0.0001); and (2) respondents who initially failed to
identify the genetics risks on Protocol A but did so on Protocol B
shifted their risk judgments a great deal (P3= 1.4, t = 3.11, p = 0.003),
and female respondents who did this rated the risks of Protocol B
much higher than did males (f3 = 1., t = 2.68, p = 0.01).
Discussion
These studies suggest that respondents on average perceive risks
from germ-line genetics research with identified human tissues as
substantially greater than minimal. Such research involves the generation of information about individuals and family members, posing
risks from possible breaches of confidentiality and disclosure of information to those who do not want to, -or who have no right to, know. The
results also suggest that when tissues are stored in a manner permitting
identification of individuals, then the mere availability of the tissues
may be perceived as posing more than minimal risk because of the
uncertainty about the uses to which they might be put.
If the storage of tissues for future studies of germ-line genetic
mutations presents more than minimal risk to identifiable subjects, then
special attention should be given to any clinical or research practices
from which excess human tissues will be potentially available for future
research. While most research with stored tissues currently does not
involve study of germ-line genetic mutations, there appears to be
increasing demand as genetic technology burgeons. This has
implications for the use of previously collected tissues, as well as for the
prospective collection of tissues for both clinical and research purposes.
First, it seems clear from these results that germ-line genetics
research using stored tissues should only proceed either with the fully
informed consent of identifiable subjects, or in the alternative, with
tissues that have been completely and irreversibly de-identified or made
anonymous. Waiver of consent in protocols using identifiable tissues is
not permissible ethically or under the federal rules when the research
poses more than minimal risk to subjects.
8 Risk- Health, Safety & Environment 235 [Summer 1997]

Second, for prospective collection of samples exclusively for
research or as an adjunct to clinical care, informed consent of subjects is
required, as is review of proposed research protocols by the full IRB.
Because of the simple procedures involved in collecting blood or other
DNA-bearing tissues, research involving them often has been classified
as minimal risk and therefore eligible for expedited review without
detailed examination of the specific protocol. This is no longer
appropriate, because genetic technology raises unique informationrelated risks. Protocols involving prospective collection of tissues must
address issues of tissue disposition, and if storage is planned, express
informed consent to that storage should be secured.
A possible critique of the survey of discussion forum participants
presented here is that very few of the list subscribers actually responded
to the survey. However, we treat the respondents as a convenience
sample, and we need not extrapolate these results to be generalized to
the surveyed population (or to the greater population of bioethicists,
lawyers, and clinician/researchers interested in these issues, who are
likely not truly represented on all relevant dimensions by those who
subscribe to the discussion groups). Rather, these results reflect in part
the perceptions of the risks of tissue storage and genetics research held
by a learned and interested group of individuals who self-selected to
respond to the survey.
We used a "within-subject" experimental manipulation to specifically study whether the risks attendant to storage of identifiable tissues
and potential use in germ-line genetics studies are salient, and whether
individuals think the genetics-related risks are more than minimal. Less
than half (44%) of the respondents initially identified the risks
attendant to germ-line genetics studies in a general statement about
research of the causes of disease, while 78% did so when the protocol
specifically called for storage for future use in such studies. The study
manipulation effectively got subjects to address the genetics-related
risks, and a majority of them (74%) rated the riskiness of the storage of
blood in identified form for use in future genetics research as greater
than minimal. One primary concern about these results is that more
respondents did not perceive the genetics-related risks and rate these
risks as greater than minimal, but this is not unexpected given broad
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differences in individual risk perceptions and the rapidity with which
genetic technologies - and societal responses thereto - are evolving.
Another possible critique of this study is that the research protocols
described to subjects were too vague to elicit meaningful responses.
Certainly, no IRB would approve any protocol submitted to them in
such general terms. Nonetheless, the extreme generality of the
described protocol was necessary to get people to think about the uses
to which a simple blood sample could be put. Many respondents did
just that, raising questions about what would be done, including in
particular concerns about whether the samples would be identified or
linked with subjects' identities and whether they would be used in
genetics research. Others focused on the physical risks of a blood draw,
and their limited focus on that procedure highlights the purpose of this
study. Until expressly spelled out, the risks from potential uses for
excess tissues - storage of which is a common practice in many clinical
laboratories - was not salient to more than half of the respondents on
the first protocol.
Had we presented a detailed protocol describing the planned
research, the issue of disposition of the excess sample would have been
less salient, as it is in real research. Simply, protocols are complex, and
IRBs already have many issues they must address, often involving life
and death and severe health risks from diseases and innovative medical
care. Information related risks, conditional upon future studies
performed with inadequate protections for identifiable subjects, may
just not be substantial enough to earn an IRB's attention. Yet,
disposition of tissues is important and must be addressed explicitly at
the time of IRB approval, before securing informed consent and
collecting samples. Research, as well as the IRB's review, might be
facilitated by developing institution-wide procedures for managing
human tissues in clinical care and research, addressing the concerns
17
raised by the prospects for future uses of identifiable tissues.
17 One model for protecting subjects is to create an institutional tissue trustee, who
may establish a one-way link between clinical information and tissue sources and
research resources, ensuring that researchers cannot identify individual subjects and
that information generated in research is prevented from flowing backwards towards
the clinical record. See, Jon F. Merz et al., Use of Human Tissues in Research:
Clarifying Clinician and Researcher Roles and Information Flows, 45 J. Investigative
Med. 252 (1997).
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Conclusion
Genetics technology has unleashed a new set of concerns regarding
uses of potentially generated medical information. These concerns
make it more important to protect the confidentiality of information
and to plan - before the research is done - for the types of
information apt to be generated and to plan what will be done with that
information. Whether using tissues taken from people for a specific
research project or tissues left over from clinical or other research uses,
issues about the specific consent of subjects to use of identifiable
materials in genetics research must be addressed by investigators and
IRBs. Recent commentary strongly suggests that germ-line genetics
research poses more than minimal risk to identifiable subjects
(including the person from whom the tissues were taken as well as
family members to whom any genetic information may apply), and
most of the respondents in this survey agreed. Moreover, storage of
tissues in identifiable form itself raises concerns about future uses,
perhaps posing more than minimal risk to people because of the
uncertainty about what might be done with those tissues. Thus,
clinicians and investigators need to think about their methods of storing
and using tissues or making them available to other researchers for
study. If excess tissues will not be needed for clinical care, then
identifiers and linking codes should be destroyed. At the least, patient
consent for storage and recontact can be secured at the time the tissues
are obtained, if use of the tissues is foreseeable. Investigators and IRBs
should explicitly consider the disposition of excess tissues collected from archives or from human subjects - in planned research, and take
steps to minimize the confidentiality and information-related risks in
approved protocols.

